| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Tetracaine HCl Basic Information:
Pharmaceutical-Grade Anesthetic Purity HCl Powder CAS 136-47-0: Tetracaine, Lidocaine
Lidocaine hydrochloride undergoes rapid metabolism by the liver, with both metabolites and unchanged drug being excreted by the kidneys. The biotransformation process includes oxidative N-dealkylation, ring hydroxylation, amide linkage cleavage, and conjugation. N-dealkylation, the primary biotransformation pathway, produces the metabolites monoethylglycinexylidide and glycinexylidide. These metabolites exhibit pharmacological and toxicological actions similar to, but less potent than, Lidocaine hydrochloride. Approximately 90% of administered Lidocaine hydrochloride is excreted as various metabolites, with less than 10% being excreted unchanged. The chief metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline.
Lidocaine HCl is a potent amide local anesthetic.
As the dosage increases, both its efficacy and toxicity rise, with an anti-convulsive effect observed at sub-toxic plasma concentrations.
Blood concentrations exceeding 5μg ? ml-1 may induce convulsions.
){kind=link}